Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin

The pharmacokinetic and pharmacodynamic parameters of torasemide were compared after intravenous administration at a dose of 2 mg/kg to diabetic rats induced by alloxan (DMIA) or streptozotocin (DMIS), and their respective control rats. It was reported that torasemide was mainly metabolized via CYP2C11 in rats and the expression and mRNA level of CYP2C11 decreased in DMIA and DMIS rats. Hence, it could be expected that the time‐averaged nonrenal clearance (Clnr) of torasemide could be slower in the diabetic rats. As expected, the Clnr values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats. However, the time‐averaged renal clearance (Clr) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate‐dependent timed‐interval Clr of torasemide in rats. The comparable time‐averaged total body clearance (Cl) values between the diabetic and control rats were due to partially compensated Clr in the diabetic rats. The 8 h urine output and diuretic efficiency increased significantly in the diabetic rats due to significantly greater 8 h urinary excretion of unchanged torasemide and at least partly due to an increase in urine output in diabetes per se (without administration of any drugs). Copyright © 2005 John Wiley & Sons, Ltd.

[1]  M. Lee,et al.  Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. , 2005, International journal of pharmaceutics.

[2]  Ji Young Kim,et al.  Dose‐independent pharmacokinetics of torasemide after intravenous and oral administration to rats , 2005, Biopharmaceutics & drug disposition.

[3]  J. Kwon,et al.  Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  So H. Kim,et al.  Effect of CYP3A1(23) Induction on Clarithromycin Pharmacokinetics in Rats with Diabetes Mellitus , 2005, Antimicrobial Agents and Chemotherapy.

[5]  Y. Choi,et al.  Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  W. L. Chiou,et al.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[7]  M. Gibaldi,et al.  Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[8]  Sang -Geon Kim,et al.  Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. , 2004, Journal of pharmaceutical sciences.

[9]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[10]  So H. Kim,et al.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide , 2003, The Journal of pharmacy and pharmacology.

[11]  E. J. Kim,et al.  Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant nagase aalbuminemic rats , 2003 .

[12]  D. Lewis.  Guide to Cytochromes P450 : structure and function , 2001 .

[13]  Y. Zhang,et al.  [Changes of CYP2E1 activity in diabetic rat model]. , 1998, Yao xue xue bao = Acta pharmaceutica Sinica.

[14]  So H. Kim,et al.  Pharmacokinetics of a new carbapenem, DA‐1131, after intravenous administration to rats with alloxan‐induced diabetes mellitus , 1998, Biopharmaceutics & drug disposition.

[15]  E. Mutschler,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Torasemide , 1998, Clinical pharmacokinetics.

[16]  N. Sugioka,et al.  Effect of Glycosylation on Carbamazepine‐Serum Protein Binding in Humans , 1997, Journal of clinical pharmacology.

[17]  J. Miners,et al.  Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  J. Watkins,et al.  Diabetes mellitus-induced alterations of hepatobiliary function. , 1995, Pharmacological reviews.

[19]  R. Mehvar.  Effect of experimental diabetes mellitus on the pharmacokinetics of atenolol enantiomers in rats. , 1991, Journal of pharmaceutical sciences.

[20]  P. Fratino,et al.  Serum Protein Binding of Phenytoin and Valproic Acid in Insulin‐Dependent Diabetes Mellitus , 1987, Therapeutic drug monitoring.

[21]  J. Watkins,et al.  Biliary excretion of organic anions in diabetic rats. , 1986, The Journal of pharmacology and experimental therapeutics.

[22]  W. Jusko,et al.  Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. , 1984, Journal of pharmaceutical sciences.

[23]  T. Guentert,et al.  Comparison of Equilibrium Times in Dialysis Experiments Using Spiked Plasma or Spiked Buffer , 1982 .

[24]  W. L. Chiou.  New calculation method of mean total body clearance of drugs and its application to dosage regimens. , 1980, Journal of pharmaceutical sciences.

[25]  W. L. Chiou.  New calculation method for mean apparent drug volume of distribution and application to rational dosage regimens. , 1979, Journal of pharmaceutical sciences.